Atara Biotherapeutics (ATRA) Now Covered by Mizuho
Mizuho started coverage on shares of Atara Biotherapeutics (NASDAQ:ATRA) in a report issued on Tuesday, The Fly reports. The firm issued a buy rating on the biotechnology company’s stock.
Other analysts also recently issued research reports about the stock. BidaskClub raised shares of Atara Biotherapeutics from a sell rating to a hold rating in a research report on Tuesday, November 20th. Zacks Investment Research raised shares of Atara Biotherapeutics from a sell rating to a hold rating in a research report on Friday, December 7th. Finally, Cowen reaffirmed a buy rating on shares of Atara Biotherapeutics in a research report on Friday, November 30th. Two research analysts have rated the stock with a sell rating, three have given a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus target price of $47.80.
Shares of NASDAQ:ATRA opened at $35.44 on Tuesday. Atara Biotherapeutics has a 52-week low of $27.85 and a 52-week high of $54.45.
In other news, EVP Christopher Haqq sold 775 shares of the firm’s stock in a transaction that occurred on Thursday, November 15th. The shares were sold at an average price of $33.81, for a total transaction of $26,202.75. Following the completion of the sale, the executive vice president now owns 285,580 shares of the company’s stock, valued at $9,655,459.80. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Joe Newell sold 1,500 shares of the firm’s stock in a transaction that occurred on Thursday, November 1st. The stock was sold at an average price of $35.00, for a total transaction of $52,500.00. Following the sale, the insider now directly owns 33,358 shares of the company’s stock, valued at approximately $1,167,530. The disclosure for this sale can be found here. Insiders sold 65,649 shares of company stock valued at $2,413,499 in the last ninety days. 10.60% of the stock is owned by corporate insiders.
Hedge funds have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC acquired a new stake in shares of Atara Biotherapeutics during the third quarter worth approximately $103,000. SG Americas Securities LLC acquired a new stake in shares of Atara Biotherapeutics during the third quarter worth approximately $108,000. Great West Life Assurance Co. Can grew its position in shares of Atara Biotherapeutics by 100.1% during the second quarter. Great West Life Assurance Co. Can now owns 3,309 shares of the biotechnology company’s stock worth $121,000 after buying an additional 1,655 shares in the last quarter. Meeder Asset Management Inc. acquired a new stake in shares of Atara Biotherapeutics during the fourth quarter worth approximately $128,000. Finally, Bank of Montreal Can grew its position in shares of Atara Biotherapeutics by 6.2% during the fourth quarter. Bank of Montreal Can now owns 5,183 shares of the biotechnology company’s stock worth $180,000 after buying an additional 302 shares in the last quarter.
About Atara Biotherapeutics
Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.
Featured Story: Investing strategies using the yield curve
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.